Pages that link to "Q42723835"
Jump to navigation
Jump to search
The following pages link to EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors (Q42723835):
Displaying 50 items.
- Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders (Q26765419) (← links)
- Advances in Alzheimer's disease drug development (Q26849352) (← links)
- Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach (Q27693356) (← links)
- Secreted Isoform of Human Lynx1 (SLURP-2): Spatial Structure and Pharmacology of Interactions with Different Types of Acetylcholine Receptors (Q29871448) (← links)
- Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders (Q30372351) (← links)
- Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats (Q30391389) (← links)
- R-( ) and S-(-) isomers of cotinine augment cholinergic responses in vitro and in vivo (Q30392403) (← links)
- Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia (Q30428422) (← links)
- Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor (Q30453198) (← links)
- The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model (Q30577199) (← links)
- Scopolamine provocation-based pharmacological MRI model for testing procognitive agents. (Q30884365) (← links)
- A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia (Q33620592) (← links)
- Drug candidates in clinical trials for Alzheimer's disease (Q33916749) (← links)
- The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment (Q33920257) (← links)
- Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats (Q34287941) (← links)
- Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations? (Q34458090) (← links)
- Lynx1 shifts α4β2 nicotinic receptor subunit stoichiometry by affecting assembly in the endoplasmic reticulum. (Q34467639) (← links)
- Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia (Q34481351) (← links)
- Immunolesion-induced loss of cholinergic projection neurones promotes β-amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice (Q34659234) (← links)
- AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation (Q35111465) (← links)
- Marine natural products acting on the acetylcholine-binding protein and nicotinic receptors: from computer modeling to binding studies and electrophysiology. (Q35136084) (← links)
- Cognition in movement disorders: where can we hope to be in ten years? (Q35211553) (← links)
- Divergent effects of the 'biased' 5-HT1 A receptor agonists F15599 and F13714 in a novel object pattern separation task. (Q35538516) (← links)
- Advances in recent patent and clinical trial drug development for Alzheimer's disease (Q35738142) (← links)
- The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia (Q36088364) (← links)
- Identification and in vitro pharmacological characterization of a novel and selective α7 nicotinic acetylcholine receptor agonist, Br-IQ17B. (Q36287717) (← links)
- Nicotinic receptors in neurodegeneration (Q36828916) (← links)
- The potential role of dopamine D₃ receptor neurotransmission in cognition. (Q37106827) (← links)
- Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker (Q37258840) (← links)
- Human brain imaging of α7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy (Q37691176) (← links)
- Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. (Q38022265) (← links)
- Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia (Q38066550) (← links)
- Animal models of Alzheimer disease: historical pitfalls and a path forward (Q38209146) (← links)
- Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies (Q38225930) (← links)
- Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status (Q38253573) (← links)
- Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication (Q38286246) (← links)
- Development of [(18)F]ASEM, a specific radiotracer for quantification of the α7-nAChR with positron-emission tomography (Q38558845) (← links)
- The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia (Q38560778) (← links)
- Cognitive impairment in schizophrenia: the great unmet need (Q38673548) (← links)
- Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. (Q38699013) (← links)
- Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries (Q38718345) (← links)
- What is the promise of nicotinergic compounds in schizophrenia treatment? (Q38811805) (← links)
- Understanding the Bases of Function and Modulation of α7 Nicotinic Receptors: Implications for Drug Discovery (Q38837028) (← links)
- Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets? (Q38962792) (← links)
- Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease (Q39041214) (← links)
- α7-nAChR agonist enhances neural plasticity in the hippocampus via a GABAergic circuit (Q39364167) (← links)
- Amyloid beta: structure, biology and structure-based therapeutic development (Q39437881) (← links)
- MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs (Q41456540) (← links)
- A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. (Q45961748) (← links)
- Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats (Q46490757) (← links)